(13) analyzed the frequency of clinical toxicity phenotypes in relation to the type of ICI used, and observed that in patients treated with anti-PD-L1 therapy, myositis and limbic encephalitis phenotypes predominated, while in patients treated with anti-CTLA-4 +/- an anti-PD-L1, polyradiculoneuropathy and meningitis phenotypes were more prevalent. Here, CTLA4 is linked to meningitis.